🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New Delhi
Clinical trial register · India

Clinical Trials in New Delhi

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
Kolkata 54 Delhi 40 Bangalore 39 New Delhi 38 Mumbai 37
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Liver and Biliary Sciences, India46 AstraZeneca38 Novartis Pharmaceuticals22 Bristol-Myers Squibb18 Eli Lilly and Company17 Clear sponsor filter
Site location
Kolkata54 Delhi40 Bangalore39 New Delhi38 Mumbai37
All 76 locations
Target enrolment
to
38 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Active, closed
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
893
Bangalore, Mohali, Mysuru, Nagpur, New Delhi, Vadodara, Varanasi
2021-05-10
Active, closed
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715Breast Cancer; HER2-positive; Metastatic
AstraZeneca
Phase 3
1,157
Ahmedabad, Bangalore, Bengaluru, Calicut, Gurgaon, Mysuru, Nashik, New Delhi
2021-04-26
Active, closed
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
358
Mumbai, Namakkal, New Delhi, Varanasi
2020-12-16
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
AstraZeneca
Phase 3
866
Bengaluru, Calicut, Kolkata, Marg Jaipur, New Delhi, Surat, Thiruvananthapuram
2020-07-24
Active, closed
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
587
Belagavi, Bengaluru, Gurgaon, Kolkata, New Delhi, Pune
2019-07-02
Active, closed
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123Triple Negative Breast Neoplasms
AstraZeneca
Phase 3
923
Bangalore, Gurgaon, Kolkata, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2019-06-25
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
AstraZeneca
Phase 3
908
Bangalore, Hyderabad, Kolkata, Mumbai, New Delhi
2019-04-29
Active, closed
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235Biliary Tract Neoplasms
AstraZeneca
Phase 3
810
Gurgaon, Kolkata, Mumbai, New Delhi
2019-04-16
Recruiting
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
NCT03813407Hyperkalaemia
AstraZeneca
Phase 3
140
Bhubaneswar, Gurgaon, New Delhi
2019-04-02
Active, closed
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
NCT03778229Carcinoma
AstraZeneca
Phase 2
367
Bangalore, Chennai, Kolkata, New Delhi
2019-01-09
Active, closed
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
AstraZeneca
Phase 3
1,246
Gurgaon, Hubli, Kolkata, Mysuru, Nagpur, Nashik, New Delhi, Pune
2018-09-27
Active, closed
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
NCT03521154Non Small Cell Lung Cancer (Stage III)
AstraZeneca
Phase 3
216
Bangalore, Gurgaon, Hubli, Karamsad, Kolkata, Nashik, New Delhi
2018-07-19
Active, closed
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02542293Non Small Cell Lung Carcinoma NSCLC
AstraZeneca
Phase 3
953
Ahmedabad, Bangalore, Chennai, Gurgaon, Karamsad, New Delhi
2015-11-03
Rows per page Showing 26–38 of 38
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/new-delhi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.